Latest E2112 Stories
Entinostat is being investigated in patients with advanced hormone receptor-positive breast cancer by the ECOG-ACRIN Cancer Research Group in its latest trial, E2112. Philadelphia, PA, and Waltham, MA (PRWEB) March 20, 2014 The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and Syndax Pharmaceuticals, Inc., announced today that patient recruitment has begun for E2112, a randomized phase III clinical trial of Syndax’s entinostat in treatment of patients with advanced breast cancer. The...
- The offense of persistently instigating lawsuits, typically groundless ones.
- An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
- Sale or purchase of positions in church or state.